FairJourney Biologics, an established company with a highly successful ten-year track record of partnerships with emerging biotech, established biopharma and large pharma, offers a range of services and support for antibody discovery, engineering and production.
More recently, FairJourney Biologics has been joined by specialists in the field such as Tariq Ghayur (formerly Abbvie) and Rene Hoet (formerly Bayer), creating a panel of available scientists as service to support complex antibody projects.
From target validation up to cell line development and pre-CMC reporting, FairJourney Biologics is a one stop shop leader in antibody services. As of 2022, the company has a headcount of above 200 staff members and a track record of more than 800 projects on a variety of areas.
News
All news
Porto. Leading Investors presented to the QSP Summit 2022 audience
News
678 days ago
Porto. Leading Investors highlighted at NOS Primavera Sound
News
696 days ago
Porto has nine companies among the 500 fastest growing in Europe, Middle East and Africa
News
1371 days ago
Porto company becomes world-leader in research and manufacturing of antibodies
News
1456 days ago